...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

Chicagoest, ....Yes I see that. What is the trial number you are referencing? 

Koo

Share
New Message
Please login to post a reply